Foghorn Therapeutics : Provides Second Quarter 2022 Financial and Corporate Update - Form 8-K

Foghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update





-FHD-286 dose escalation Phase 1 study in metastatic uveal melanoma continues... | August 9, 2022

Related Keywords

United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Karin Hellsvik ,Michael Lampe ,Adrian Gottschalk ,Hans Vitzthum ,Linkedin ,Twitter ,Foghorn Therapeutics Inc ,Drug Administration ,Nasdaq ,Exchange Commission ,Company Annual Report On Form ,Development Expenses ,Therapeutics Inc ,Foghorn Therapeutics Provides Second Quarter ,Corporate Update ,Gene Traffic Control ,Merck Collaboration ,Pipeline Advancement Foghorn ,Strong Balance Sheet ,Lilly Collaboration Agreement ,Annual Report ,Quarterly Reports ,Consolidated Statements ,Months Ended June ,Foghorn Therapeutics ,Lifesci Advisors ,Foghorn Therapeutics Inc Stock Exchange ,News ,Information ,Press Release ,Foghorn ,Herapeutics ,Rovides ,Second ,Quarter ,022 ,Financial ,End ,Corporate ,Nose ,Escalation ,Hase , ,Study ,N ,Metastatic ,Veal ,Elanoma Fhtx Us3441741077 ,